Bayer AG (ADR)

  • 4 Reasons I'm Not Bullish on This Biotech

    By Kanak Kanti - August 14, 2013 | Tickers: AZN, BAYRY.PK, NBIX

    Neurocrine Biosciences (NASDAQ: NBIX) has gained significantly in the last few months based on positive trial results, news of collaborations, and the general unfathomable nature of the stock market. However, this stock looks like a value trap right now, for four reasons.

    Few products in the near-term pipeline

    Neurocrine has 11 programs in various stages of research and development, of which six programs are in clinical stages. However, except for more »

  • What to Watch for at These 3 Drug Firms

    By Phillip Woolgar - August 14, 2013 | Tickers: BAYRY.PK, MNK, NVS

    In light of three indicators that point to increased sales at drug companies -- an economic recovery, an aging baby boomer population, and Obamacare -- medication firms are gearing up for major profits. If they aren't already making changes, they likely will in the next couple years, as the unemployment rate improves to 7.4% from over 10%, as baby boomers develop medication dependency, and as Obamacare embeds itself next year more »

  • This Pharma Stock Is Ready to Reach New Heights

    By Kanak Kanti - August 12, 2013 | Tickers: BAYRY.PK, REGN, SNY

    Earlier this year, in May, Regeneron Pharmaceuticals (NASDAQ: REGN) was soaring on news of FDA approval of the Eylea injection. The market valued the company at almost $27 billion at that time. It has come down quite a bit now to nearly $25 billion. Things are now happening again at this counter, with the company preparing to submit an application for approval of Eylea for a new indication, and an more »

  • Who Could Buy Onyx and at What Price?

    By Kanak Kanti - July 12, 2013 | Tickers: BAYRY.PK, CELG, ONXX

    Note: This article has been amended to better reflect the development of each mentioned drug.

    Recently Onyx Pharmaceuticals (NASDAQ: ONXX) rejected a $10 billion takeover offer from Amgen. However, after that it hired an investment banker for finding a suitable buyer. With three cancer drugs in its portfolio, Onyx is an attractive takeover target for many larger biotechs. Investors want to consider if another offer or two is upcoming, and more »

  • Who Is the Best Suitor for Onyx?

    By Vikas Shukla - July 8, 2013 | Tickers: AMGN, BAYRY.PK, ONXX

    Cancer-drug maker Onyx Pharmaceuticals (NASDAQ: ONXX) recently rejected an $8.7 billion unsolicited acquisition offer from Amgen (NASDAQ: AMGN). Onyx also said that it is looking for potential suitors. The move has triggered speculations of a bidding war, sending the stock up 51.27% on Monday to $131.33.

    Amgen had offered to pay $120 per share in cash, a 38.2% premium to Onyx’s closing price of $86 more »

  • Avoid This Biotech Investment, For Now

    By Mohsin Saeed - July 3, 2013 | Tickers: AMGN, BAYRY.PK, ONXX

    Mergers and acquisitions have always been a big part of the biotechnology industry, and the patent cliff has further increased M&A activity. We are only mid-way into 2013, but the biotech industry has already seen M&A of over $93.6 billion, as the generic threat and empty pipelines are forcing big-pharmaceutical players to adopt aggressive M&A strategies.

    Onyx Pharmaceuticals (NASDAQ: ONXX) has said that it has rejected more »

  • A Billion-Dollar Anticancer Technology in the Making

    By Kanak Kanti - July 2, 2013 | Tickers: BAYRY.PK, IMGN, SGEN

    Anticancer drugs typically damage normal cells as well as cancer cells. Using a breakthrough technology, a midsize biotech company is developing a process to deliver anticancer drugs right inside a cancerous cell, selectively destroying it while sparing healthy cells. If successful, this will become a technology worth billions of dollars.

    Monoclonal antibodies vs. conjugated antibodies

    Monoclonal antibodies, or mAbs, block specific proteins that help cancer cells to grow. They may more »

  • Will This Company Dominate the Multiple Sclerosis Market?

    By Kanak Kanti - June 12, 2013 | Tickers: BAYRY.PK, BIIB, TEVA

    With one product already on the market, one recently approved and four more in various stages of clinical development, Biogen Idec (NASDAQ: BIIB) has a very strong presence in the multiple sclerosis space. Multiple sclerosis is a debilitating disease that affects 2.5 million people worldwide, and 400,000 Americans annually, according to WebMD.

    Making Biogen Idec's position even stronger, the company recently submitted a biologics license application more »

  • A Strategic Healthcare Deal With an Expensive Price Tag

    By Anh HOANG - May 8, 2013 | Tickers: BAYRY.PK, CPTS, HOLX

    Recently, Bayer AG (NASDAQOTH: BAYRY.PK) has announced that it will acquire Conceptus (NASDAQ: CPTS) at an average of $31 per share in cash, with a total transaction value of $1.1 billion. The offering price represented a 20% premium to its trading level of $25.90 on April 26. Conceptus’ shareholders must be quite happy, as Conceptus’ share price has experienced a sweet gain of as much as 47.7 more »

  • The Oncology Stock to Buy Today

    By Shas Dey - March 29, 2013 | Tickers: AVEO, BAYRY.PK, CELG, ONXX

    Onyx Pharmaceuticals (NASDAQ: ONXX) is trying to shrug off its dependency on partners, and transform itself from a royalty and drug-development company into a full-fledged biopharmaceutical company. This was evident when the company’s CEO, N. Anthony Coles, said at an investors meet that, "The way to build a successful, sustainable business is through acquisitions, either companies or products -- even licensing deals."

    Onyx’s CEO has things going for him more »

  • Consider these International Health Care Stocks

    By Bob Ciura - January 30, 2013 | Tickers: AZN, BAYRY.PK, NVS, SNY

    Companies in the health care sector provide essentials to both customers and investors: namely, their products and their dividends.  One of the things I look for in a company is products that people need no matter the prevailing economic climate.  Medicines and consumer health products certainly fit that bill.  While the U.S-based health care giants are well-known to most investors, the following is a list of international competitors in more »

  • Nutrition's Market Domination with the Schiff-Beckitt Merger

    By Josef Ray Dagatan - December 5, 2012 | Tickers: BAYRY.PK, RBGPF, SHF

    Schiff Nutrition International (NYSE: SHF) is known to be one of the leading companies that manufactures, develops, distributes, markets, and sells sports nutrition products, vitamins, and other nutritional supplements, under different brand names like MegaRed, Move Free, Airborne, Tiger's Milk, Digestive Advantage, and Schiff Vitamins. It offers products mainly for care for joints, immunological support, digestive health, and health of the heart. By supporting and developing new and stronger more »

  • The Bayer-Schiff Deal is Just the Start

    By Tony Daltorio - November 2, 2012 | Tickers: BAYRY.PK, KO, PFE, SNY, SHF

    Pharmaceutical companies are finding that the old model of researching, developing and marketing drugs is no longer working. The competition from generic drug makers (after patent expirations) is just too tough. So the pharmaceutical companies in recent years have gone on a diversification spree, in search of more stable sources of income. This has led the firms to buying companies in diverse areas such as animal health and consumer health more »

  • Would You Trade Shoulder Pain for a Heart Attack?

    By Chris Marasco - September 12, 2012 | Tickers: BAYRY.PK, BMY, MRK, PFE

    The hot industries get all the press.  The media keeps explaining how social media allows companies to have one-on-one relationships with customers and to target each customer directly.  This is why social media expert Gary Vaynerchuk says that marketing is about to get really, really hard.

    But the personalization trend is across the board.  Health care, for instance, is quickly moving (for health care this means years) toward personalized medicine more »

  • Regeneron's Vision for the Future

    By Jonathan Lim - August 27, 2012 | Tickers: ALPMY.PK, BAYRY.PK, REGN, RHHBY, SNY

    "Great company, but not at that price" is a line I use a lot these days. It sure can be tempting to deviate from a value-focused strategy, especially when all sorts of glamorous growth stories are commanding billion-dollar valuations and your Benjamin Graham cigarette-butt stocks aren’t featured on CNBC every day and aren’t sending you glossy annual reports full of exciting news. But I’m managing to stick more »

  • Trius Therapeutics Holds Steady and Reports Positive Financials

    By John Eastman - August 10, 2012 | Tickers: BAYRY.PK, TSRX

    There is something to be said for slow, steady, and cerebral; especially, if you are invested in a biopharmaceutical firm. This industry does not turn out products overnight. It is a slow, long and grueling process of development, clinical trial testing, FDA maneuvering, safe (GMP) good manufacturing practice production, effective distributing and marketing, and obtaining key partners. And then there is the money! Costs of clinical trial testing are exorbitant more »

  • U.S. Biofirms Progress Offshore with Diverse Deals

    By John Eastman - May 14, 2012 | Tickers: BAYRY.PK, TSRX

    The U.S. Federal Drug Agency (FDA) is known to be one of the best in the world for screening, approving, and the regulation of safe and effective drugs for its population. The agency is quite diverse, with divisions allocated for various medical conditions and diseases, oncology, hematology, and ophthalmology, among others. Companies in the biotech, biopharmaceutical, and even big pharma industries generally report receiving cooperation and advice from the more »